Protagonist Therapeutics (PTGX) Tax Provisions (2018 - 2026)

Protagonist Therapeutics has disclosed Tax Provisions across 6 years of filings, most recently posting -$1.5 million for Q1 2026.

• Tax Provisions for Q1 2026 came in at -$1.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$634000.0 (down 171.24% YoY), and the FY2025 annual result was $838000.0, down 80.14% from the prior year.
• Tax Provisions came in at -$1.5 million for Q1 2026 at Protagonist Therapeutics, down from $666000.0 in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $3.3 million in Q1 2024 to a low of -$1.5 million in Q1 2026.
• The 3-year median for Tax Provisions is $200000.0 (2025), against an average of $508000.0.
• Peak annual rise in Tax Provisions reached 128.57% in 2025, while the deepest fall reached 66.53% in 2025.
• Protagonist Therapeutics' Tax Provisions stood at $2.0 million in 2024, then slumped by 66.53% to $666000.0 in 2025, then slumped by 325.23% to -$1.5 million in 2026.
• The last three Tax Provisions figures came in at -$1.5 million (Q1 2026), $666000.0 (Q4 2025), and $200000.0 (Q2 2025), per Business Quant data.